ProKidney receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
ProKidney Corp (PROK)
ProKidney Corp stock price live, this page displays NASDAQ PROK stock exchange data. View the PROK premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the ProKidney Corp real time stock price chart below.
What Is the ProKidney Corp Stock Price Today?
The ProKidney Corp stock price today is 2.435.
What Is the Stock Symbol for ProKidney Corp?
The stock symbol for ProKidney Corp is ""PROK.""
What Stock Exchange Does ProKidney Corp Trade On?
ProKidney Corp is listed and trades on the NASDAQ stock exchange.
Is ProKidney Corp a Good Stock to Buy?
Determining whether ProKidney Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PROK quote. (ISIN: US74291D1046)
What Is the ProKidney Corp Stock Price Today?
The ProKidney Corp stock price today is 2.435.
What Is the Stock Symbol for ProKidney Corp?
The stock symbol for ProKidney Corp is ""PROK.""
What Stock Exchange Does ProKidney Corp Trade On?
ProKidney Corp is listed and trades on the NASDAQ stock exchange.
Is ProKidney Corp a Good Stock to Buy?
Determining whether ProKidney Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PROK quote. (ISIN: US74291D1046)
NASDAQ
Currency in USD
2.435
+0.025(+1.04%)
Real-time Data·
Fair Value
An estimate of a ProKidney's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.350
2.480
52 wk Range
0.460
7.130
PROK Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
PROK is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a ProKidney's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.3502.480
52 wk Range
0.4607.130
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PROK Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a ProKidney's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
5.833
Upside
+139.56%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
- Form 8K ProKidney Corp For: 16 July
- Investing.com
- ProKidney receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 8K ProKidney Corp For: 16 July
- Investing.com
- Form 8K ProKidney Corp For: 15 July
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
ProKidney Corp Company Profile
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Compare PROK to Peers and Sector
Metrics to compare | PROK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPROKPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.5x | −1.3x | −0.6x | |
PEG Ratio | −0.62 | −0.05 | 0.00 | |
Price/Book | −0.7x | 1.7x | 2.6x | |
Price / LTM Sales | 1,354.1x | 8.2x | 3.3x | |
Upside (Analyst Target) | 169.7% | 279.8% | 37.4% | |
Fair Value Upside | Unlock | 25.6% | 4.5% | Unlock |
Analyst Ratings
4 Buy
3 Hold
1 Sell
Ratings:
8 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 5.833
(+139.56% Upside)
Earnings
Latest Release
Aug 12, 2025
EPS / Forecast
-0.13 / -0.15
Revenue / Forecast
220.00K / --
People Also Watch
FAQ
What Stock Exchange Does ProKidney Trade On?
ProKidney is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for ProKidney?
The stock symbol for ProKidney is "PROK."
What Is the ProKidney Market Cap?
As of today, ProKidney market cap is 690.79M.
What Is ProKidney's Earnings Per Share (TTM)?
The ProKidney EPS (TTM) is -0.56.
When Is the Next ProKidney Earnings Date?
ProKidney will release its next earnings report on 17 Nov 2025.
From a Technical Analysis Perspective, Is PROK a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has ProKidney Stock Split?
ProKidney has split 0 times.
How Many Employees Does ProKidney Have?
ProKidney has 204 employees.
What is the current trading status of ProKidney (PROK)?
As of 25 Aug 2025, ProKidney (PROK) is trading at a price of 2.44, with a previous close of 2.41. The stock has fluctuated within a day range of 2.35 to 2.48, while its 52-week range spans from 0.46 to 7.13.
What Is ProKidney (PROK) Price Target According to Analysts?
The average 12-month price target for ProKidney is USD5.83333, with a high estimate of USD10 and a low estimate of USD1. 4 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +139.56% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.